Targeted Mitochondrial Medicine: Synergistic Modulation of AMPK and NAD⁺ Salvage Pathways for Cardiometabolic Health

ABSTRACT

Background: Cellular bioenergetic decline is increasingly recognized as a root mechanism underlying cardiovascular aging, insulin resistance, and age-related metabolic syndrome. Central to this decline is the progressive depletion of nicotinamide adenine dinucleotide (NAD⁺), which impairs mitochondrial oxidative phosphorylation, sirtuin-mediated gene regulation, and nuclear-mitochondrial communication. Simultaneously, the progressive attenuation of AMP-activated protein kinase (AMPK) activity with aging dismantles the cell's principal energy-sensing scaffold, accelerating metabolic dysfunction. A biochemical feedback axis connecting AMPK activation with intracellular NAD⁺ availability through the metabolic co-regulator SIRT1 has been described, suggesting that combined pharmacological targeting of both pathways may yield synergistic therapeutic effects.

Objective: This review critically evaluates the mechanistic and clinical evidence for synergistic modulation of the AMPK pathway and NAD⁺ salvage pathways using endogenous precursors (nicotinamide riboside [NR] and nicotinamide mononucleotide [NMN]), pyrroloquinoline quinone (PQQ), and AMPK-modulating agents, with particular focus on preventive cardiometabolic medicine and the emerging paradigm of longevity medicine.

Methods: A structured narrative review of preclinical and clinical literature published between 2005 and 2026 was conducted, drawing on primary mechanistic studies, clinical trials, and authoritative reviews indexed in PubMed/MEDLINE, Semantic Scholar, and ClinicalTrials.gov.

Conclusions: The AMPK–NAD⁺–SIRT1 axis constitutes a functionally integrated bioenergetic network with significant implications for preventive cardiology and metabolic medicine. Preclinical evidence strongly supports synergistic activation of this network. Clinical evidence confirms that NAD⁺ precursors safely elevate intracellular NAD⁺ and offer early signals of cardiometabolic benefit, while AMPK modulators such as berberine demonstrate clinically significant improvements in insulin sensitivity and lipid parameters. Formal combination strategies await adequately powered randomized trials.

Keywords: NAD⁺, AMPK, SIRT1, NMN, NR, berberine, mitochondrial biogenesis, PQQ, longevity medicine, metabolic syndrome, preventive cardiology

1. INTRODUCTION

The concept of mitochondrial medicine as a clinical discipline has evolved considerably beyond its historical association with rare inherited respiratory chain disorders. Over the past two decades, converging evidence from molecular biology, translational physiology, and early-phase human trials has established that impairment of mitochondrial bioenergetics — at the level of coenzyme availability, electron transport chain efficiency, and energy-sensing signaling — is a shared, modifiable upstream mechanism in a spectrum of highly prevalent age-related diseases: cardiovascular insufficiency, type 2 diabetes, sarcopenia, and cognitive decline.

Despite this, the vast majority of clinically trained physicians retain only a skeletal, examination-oriented knowledge of cellular bioenergetics. Concepts such as the Krebs cycle and the electron transport chain are memorized as static biochemical diagrams and subsequently abandoned upon entry into clinical practice. This educational gap carries a consequential cost: a failure to recognize that interventions targeting the fundamental energetic currency of the cell — NAD⁺ and the adenylate energy charge sensed by AMPK — represent a mechanistically coherent and clinically actionable framework for preventive medicine.

NAD⁺ is a critical redox cofactor and signaling molecule. Its intracellular pool, maintained in large part by the salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT), declines measurably with aging across multiple human tissues, including skeletal muscle, cardiac muscle, and the brain. [^1] This decline is not merely correlative: it has been causally linked to mitochondrial dysfunction through the landmark demonstration that falling nuclear NAD⁺ disrupts mitochondrial OXPHOS subunit expression via a SIRT1-dependent pseudohypoxic mechanism, and that restoring NAD⁺ in aged mice reverses this mitochondrial decay. [^2]

In parallel, AMPK — the heterotrimeric kinase activated by an elevated AMP/ATP ratio — functions as the master energy sensor of eukaryotic cells. Its activity declines with aging and in the setting of metabolic overload, and its activation constitutes the proximate mechanism of action of two of the most widely prescribed metabolic interventions in clinical medicine: metformin and exercise. [^3]

The convergence of these pathways is not coincidental. A seminal study published in Nature by Cantó et al. (2009) demonstrated that AMPK enhances SIRT1 deacetylase activity by increasing intracellular NAD⁺ levels, linking the two pathways in a coherent regulatory circuit whose downstream effectors — PGC-1α, FOXO1/3, and mitochondrial biogenesis genes — constitute the transcriptional program of metabolic resilience. [^4]

The present review synthesizes current mechanistic understanding and clinical evidence to argue that targeted pharmacological modulation of this AMPK–NAD⁺–SIRT1 axis represents a rational, evidence-grounded approach to preventive cardiometabolic medicine.

2. PATHOPHYSIOLOGY AND MECHANISM

2.1 NAD⁺ Metabolism: Biosynthesis, Salvage, and Age-Related Decline

NAD⁺ is synthesized through three principal biosynthetic routes in mammals: (1) the de novo pathway from tryptophan via the kynurenine pathway; (2) the Preiss-Handler pathway from nicotinic acid; and (3) the salvage pathway, which recycles the nicotinamide generated by NAD⁺-consuming enzymes (sirtuins, PARPs, and CD38) back to NMN and subsequently NAD⁺ via NAMPT and NMNAT enzymes. [^5][^6] Under physiological conditions, the salvage pathway is quantitatively dominant, and NAMPT is its rate-limiting enzyme.

NAD⁺ levels decline with aging in a manner that is now well-documented across species from C. elegans to humans. [^7] The mechanistic drivers of this decline are twofold and complementary: reduced NAMPT expression diminishes synthetic flux, while the constitutive activation of NAD⁺-consuming enzymes — particularly CD38 (a NADase markedly upregulated in senescent immune cells) and PARP1 (activated by the increased genomic instability of aging) — accelerates catabolism. [^8] The net result is a progressive NAD⁺ deficit that impairs the activity of all NAD⁺-dependent signaling enzymes.

The functional consequences are broad. SIRT1 and SIRT3 are NAD⁺-dependent deacylases that govern mitochondrial biogenesis, fatty acid oxidation, the antioxidant response, and circadian metabolic rhythms; their activity decreases proportionally with NAD⁺ availability. PARP1, when chronically over-activated in the context of oxidative DNA damage, competes with sirtuins for the shared NAD⁺ substrate, creating a vicious cycle in which genomic instability further depletes the co-substrate needed for its own repair. [^9]

At the cardiovascular level, NAD⁺ pools decline in human myocardium with age, obesity, and hypertension — all established risk factors for heart failure. Preclinical studies have demonstrated that NAD⁺ replenishment protects against ischemia-reperfusion injury, reduces pathological hypertrophy, and preserves ejection fraction in multiple murine heart failure models. [^9] A 2021 review in Circulation concluded that patients with heart failure with preserved ejection fraction — a condition for which few disease-modifying therapies exist — may represent a particularly compelling target population for NAD⁺ precursor-based therapeutics. [^4]

2.2 AMPK: Architecture, Activation, and Downstream Effectors

AMPK is a heterotrimeric serine/threonine kinase composed of a catalytic α-subunit and regulatory β- and γ-subunits. The γ-subunit harbors four CBS (cystathionine β-synthase) domains that function as a structural AMP/ATP sensor: elevated AMP or ADP allosterically activates the complex and protects the activating phosphorylation at Thr172 on the α-subunit from dephosphorylation by PP2C. The primary upstream kinase for this phosphorylation is LKB1, while CaMKKβ constitutes a secondary calcium-dependent activating mechanism. [^4]

Upon activation, AMPK executes a coherent metabolic program: it phosphorylates ACC (acetyl-CoA carboxylase) to inhibit fatty acid synthesis, phosphorylates HMGCR to inhibit cholesterol synthesis, activates malonyl-CoA decarboxylase to promote fatty acid oxidation, and suppresses mTORC1 to reduce anabolic energy expenditure. Simultaneously, it activates transcriptional reprogramming through PGC-1α and FOXO transcription factors to induce mitochondrial biogenesis, mitophagy, and stress resistance. [^1] The net outcome is a shift from anabolic, energy-consuming metabolism to catabolic, energy-generating metabolism — precisely the metabolic phenotype that characterizes exercise-adapted and calorically restricted states associated with longevity.

AMPK activity declines with aging and in the context of sustained caloric excess. This decline is mechanistically consequential: experimental suppression of AMPK in model organisms accelerates metabolic aging, whereas genetic or pharmacological enhancement of AMPK activity extends healthspan in C. elegans, Drosophila, and, increasingly, murine models. [^4]

2.3 The AMPK–NAD⁺–SIRT1 Feedback Axis

The biochemical linkage between AMPK and SIRT1 was formally established by Cantó et al. (2009) in a study published in Nature. The core finding was that AMPK activation increases intracellular NAD⁺ levels in skeletal muscle, thereby enhancing SIRT1-mediated deacetylation of PGC-1α and FOXO1/3. [^4] The mechanism involves AMPK-dependent phosphorylation of PGC-1α combined with SIRT1-dependent deacetylation of the same coactivator — two post-translational modifications that act cooperatively to drive its transcriptional activity. This interaction explains why the biological effects of AMPK activation and SIRT1 activation are so extensively overlapping: they converge on the same downstream effector.

The reciprocal arm of this feedback — NAD⁺ supplementation activating SIRT1, which in turn may modulate AMPK activity through deacetylation of LKB1 — has also been characterized. Together, these interactions constitute a positive feedback loop: AMPK raises NAD⁺ → NAD⁺ activates SIRT1 → SIRT1 activates PGC-1α → PGC-1α upregulates mitochondrial biogenesis and NAMPT expression → NAMPT elevates NAD⁺ → sustaining the cycle. [^10] Disruption of this loop at any node — by aging-related NAD⁺ decline, caloric overload-induced AMPK suppression, or oxidative inactivation of SIRT1 — propagates dysfunction through the entire network.

This architecture provides the theoretical basis for synergistic pharmacological intervention: agents that restore NAD⁺ availability and agents that activate AMPK are not merely additive; they address complementary rate-limiting steps in the same integrated network.

3. CLINICAL MANIFESTATIONS OF AMPK–NAD⁺ AXIS DYSFUNCTION

Cardiovascular aging and heart failure.

Aging cardiac myocytes exhibit reduced NAD⁺/NADH ratios, impaired mitochondrial respiratory chain activity, reduced SIRT3-mediated antioxidant defense, and pathological hyperacetylation of mitochondrial proteins. The resulting energetic insufficiency — reduced ATP production per mole of substrate oxidized — is a defining characteristic of the failing heart regardless of ejection fraction. [^4]

Insulin resistance and type 2 diabetes.

In insulin-resistant skeletal muscle and adipose tissue, AMPK activity is reduced, mitochondrial content is diminished, fatty acid oxidation is impaired, and ectopic lipid deposition promotes serine phosphorylation of IRS-1, blocking insulin signaling. This metabolic inflexibility — the inability to switch between glucose and fatty acid oxidation according to substrate availability — precedes and predicts the onset of overt type 2 diabetes. [^11] NAD⁺ supplementation, by activating SIRT1 and SIRT3, directly addresses the upstream mitochondrial component of this dysfunction.

Age-related sarcopenia and reduced exercise capacity.

Skeletal muscle is among the tissues with the most pronounced age-related NAD⁺ decline. Gomes et al. (2013), in a landmark Cell publication, demonstrated that declining nuclear NAD⁺ creates a pseudohypoxic state via HIF-1α accumulation that specifically disrupts nuclear-encoded OXPHOS subunit expression — and that this process is reversible by NAD⁺ precursor administration in aged mice. [^2]

Metabolic syndrome as a clinical composite.

The clustering of central obesity, hypertriglyceridemia, reduced HDL-cholesterol, hypertension, and impaired fasting glucose represents, in mechanistic terms, a syndrome of AMPK failure and NAD⁺ insufficiency. Interventions that restore either or both arms of this axis produce measurable improvements across multiple components of the metabolic syndrome simultaneously.

4. DIAGNOSTIC AND BIOMARKER APPROACH

NAD⁺ quantification.

Whole-blood and peripheral blood mononuclear cell (PBMC) NAD⁺ levels are measurable by liquid chromatography-mass spectrometry (LC-MS/MS) and have been used as primary pharmacodynamic endpoints in clinical trials of NR and NMN supplementation. These measurements have consistently shown age-related decline and reliable repletion following precursor administration. [^12] Tissue-specific NAD⁺ quantification (e.g., muscle biopsy) remains primarily a research tool.

Metabolic surrogates.

Fasting insulin, HOMA-IR, adiponectin (particularly the high-molecular-weight isoform), triglycerides, and HDL-cholesterol serve as indirect functional indicators of AMPK and insulin signaling competence. Berberine's clinical effects on these parameters have been formally characterized in randomized trials. [^12]

Mitochondrial function proxies.

Cardiopulmonary exercise testing (VO₂max) and the derived oxygen kinetic parameters reflect integrated mitochondrial oxidative capacity. Accelerometry-based measures of physical performance, grip strength, and skeletal muscle mass (assessed by DXA or bioimpedance) provide indirect assessments of mitochondrial competence in clinical settings.

Inflammatory and redox markers.

hsCRP, IL-6, and 8-isoprostane (a lipid peroxidation marker) reflect the low-grade inflammatory and oxidative states that are both cause and consequence of AMPK–NAD⁺ axis failure.

5. MANAGEMENT AND THERAPEUTIC STRATEGIES

5.1 NAD⁺ Precursors: Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN)

Safety and bioavailability.

Multiple phase I and early phase II trials have now established that oral NR (250–1000 mg/day) and NMN (250–1200 mg/day) are well tolerated in healthy adults and effectively raise whole-blood NAD⁺ levels, typically by 40–90% above baseline. [^14] No serious adverse events attributable to supplementation have been reported across these trials. Gastrointestinal tolerability is generally good at standard doses.

Cardiovascular signals.

In a rigorously reviewed analysis published in Endocrine Reviews (2023), Bhasin et al. concluded that early human studies suggest NR supplementation modestly reduces blood pressure and improves lipid profiles in older adults with obesity or overweight, attenuates endothelial dysfunction, and may suppress inflammation in neurodegenerative contexts. The authors explicitly identified heart failure with preserved ejection fraction and metabolic syndrome as priority populations for adequately powered efficacy trials.

Metabolic effects.

Preclinical studies consistently show that NAD⁺ precursors improve glucose tolerance and insulin sensitivity in diabetic and high-fat-fed rodent models by activating SIRT1/SIRT3 and restoring mitochondrial oxidative capacity in skeletal muscle and liver. Translation to human efficacy remains incompletely established; some RCTs in people with type 2 diabetes or metabolic syndrome have shown improvements in insulin sensitivity, while others have shown attenuated effects, possibly reflecting the lower baseline NAD⁺ deficit in less severely affected populations or suboptimal precursor delivery to target tissues. [^15]

Limitations.

Several mechanistic questions remain open: the comparative bioavailability of NR versus NMN in specific tissues, the contribution of the gut microbiome to precursor metabolism, the optimal dosing interval, and the potential for long-term supraphysiological NAD⁺ to alter PARP-dependent DNA repair or cell-cycle regulation in specific oncological contexts. These uncertainties mandate cautious clinical application pending the completion of longer-duration trials. [^13]

5.2 AMPK Modulators: Berberine as a Clinical Prototype

Mechanism of AMPK activation.

Berberine inhibits mitochondrial respiratory complex I, elevating the intracellular AMP/ATP ratio and thereby allosterically activating AMPK. This mechanism is formally analogous to that of metformin, with both agents activating AMPK as a consequence of mild mitochondrial energy restraint rather than by directly binding the kinase. A seminal study by Lee et al. (2006) in Diabetes demonstrated that berberine increases AMPK activity in 3T3-L1 adipocytes and L6 myotubes, promotes GLUT4 translocation, and reduces lipid accumulation — effects that are mechanistically downstream of AMPK activation. [^16]

Downstream glycolytic and lipid effects.

AMPK activation by berberine inhibits acetyl-CoA carboxylase and HMG-CoA reductase, suppressing de novo lipogenesis and cholesterol synthesis. A study in the Journal of Lipid Research demonstrated that berberine reduces plasma LDL-cholesterol and liver fat in hyperlipidemic hamsters through AMPK-dependent inhibition of lipid synthesis, complementing its well-established effect of upregulating the hepatic LDL receptor.

Clinical trial evidence.

A randomized, double-blind, placebo-controlled trial by Pérez-Rubio et al. in 24 patients with metabolic syndrome demonstrated that berberine 500 mg three times daily for three months produced a 36% remission of the metabolic syndrome diagnosis, reduced triglycerides by approximately 40%, improved insulin sensitivity (increased Matsuda index), and significantly lowered systolic blood pressure. [^17] While this is a small trial, its findings are consistent with a larger body of clinical evidence showing berberine's effects on glycemic parameters to be comparable in magnitude to metformin in head-to-head comparisons, though with a more modest adverse effect profile.

AMPK activation and adiponectin. A mechanistically important secondary finding in berberine research is the promotion of high-molecular-weight (HMW) adiponectin multimerization via AMPK activation. HMW adiponectin is the most biologically active isoform, closely associated with peripheral insulin sensitivity. Berberine-induced AMPK activation was shown to increase the HMW/total adiponectin ratio in 3T3-L1 adipocytes — an effect abolished by AMPK knockdown. [^18]

5.3 Pyrroloquinoline Quinone (PQQ): A Mitochondriogenic Cofactor at the AMPK–NAD⁺ Interface

PQQ is a redox-active ortho-quinone found in diverse foods and in human tissues that has been characterized as a stimulator of mitochondrial biogenesis. Its primary signaling mechanism involves the phosphorylation of CREB at Ser133, which drives transcriptional activation of PGC-1α — the master regulator of mitochondrial biogenesis and a downstream effector of both AMPK and SIRT1. [^19]

Mechanistic studies by Saihara et al. (2017) demonstrated that PQQ stimulates mitochondrial biogenesis in NIH/3T3 fibroblasts through the SIRT1/PGC-1α signaling pathway, with the effect blocked by the selective SIRT1 inhibitor EX-527. Critically, PQQ treatment increased cellular NAD⁺ levels without altering total (NAD⁺ + NADH), suggesting that its biogenetic effects are attributable to a shift in the NAD⁺/NADH ratio rather than total nicotinamide pool expansion. A separate line of evidence from a murine Parkinson's disease model demonstrated that PQQ promotes mitochondrial biogenesis specifically through AMPK activation, providing direct mechanistic overlap with berberine's pathway of action. [^20]

Diet-derived and supplemental PQQ thus occupies a mechanistically complementary niche: while NAD⁺ precursors increase the substrate availability for SIRT1 and for oxidative phosphorylation, PQQ simultaneously activates the transcriptional program (via CREB/PGC-1α/SIRT1) that controls the production of new mitochondria. It addresses the structural regenerative arm of mitochondrial health that NAD⁺ precursors alone cannot fully recapitulate.

The clinical evidence base for PQQ remains notably thinner than for NR/NMN or berberine: most studies are preclinical, with human data limited to small pilots showing improvements in cognitive function, fatigue, and sleep quality. This gap between mechanistic plausibility and clinical evidence must be explicitly acknowledged.

5.4 Synergistic Combination Strategies: Theoretical Framework and Emerging Evidence

The mechanistic architecture of the AMPK–NAD⁺–SIRT1 axis described above provides a rational framework for combination pharmacotherapy targeting multiple nodes simultaneously.

The core synergistic principle is as follows:

1. NR or NMN restores the NAD⁺ substrate pool, directly enabling SIRT1, SIRT3, and PARP function, and replenishing the electron acceptor capacity of the mitochondrial respiratory chain.
2. Berberine activates AMPK via mitochondrial complex I restraint, elevating NAD⁺ via AMPK-dependent NAMPT upregulation and further enhancing SIRT1 activity through increased NAD⁺ availability.
3. PQQ activates the CREB/PGC-1α transcriptional program to drive mitochondrial biogenesis, increasing the number and quality of mitochondria in which the restored NAD⁺ pool can function.

These interventions thus address: (a) substrate availability (NAD⁺ precursors), (b) energy-sensing signal transduction (berberine/AMPK), and (c) mitochondrial structural renewal (PQQ/PGC-1α). No formal head-to-head or combination RCT testing this specific triad has been published to date. However, the AMPK–SIRT1 co-activation paradigm is supported by the landmark Nature study by Cantó et al., which demonstrated that AMPK activation by AICAR or exercise raises NAD⁺ and synergistically activates SIRT1 targets in a manner not recapitulated by either AMPK activation or NAD⁺ supplementation alone. [^4]

A 2025 theoretical mechanistic study proposed a dual SIRT1/AMPK hybrid molecule (SIRAMP-21) as a conceptual model for synergistic cardiovascular longevity therapy, citing the same positive feedback loop architecture reviewed herein. [^21] While this remains a theoretical compound, it signals the direction of the field.

Practical clinical considerations for combination use include: potential bidirectional regulation of AMPK by berberine under varying glucose conditions (bidirectional AMPK modulation relative to ambient glucose has been documented), underscoring the importance of metabolic context in determining net pharmacodynamic effects; the interaction of NMN/NR metabolism with the gut microbiome, which may vary among individuals; and the absence of long-term safety data for chronic co-administration of multiple NAD⁺-modulating agents.

6. DISCUSSION

The evidence reviewed here supports a convergent view of cellular bioenergetic aging as a condition of AMPK hyporesponsiveness and NAD⁺ insufficiency, and it identifies a mechanistically coherent set of interventions capable of addressing these deficits.

Several points merit particular emphasis from a translational perspective.

First, the clinical efficacy data for NAD⁺ precursors in humans, while encouraging in terms of safety, bioavailability, and early metabolic signals, remains substantially weaker than the preclinical evidence would predict. Bhasin et al. (2023) explicitly noted that the efficacy of NR and NMN in human trials has been lower than anticipated from preclinical studies, attributing this discrepancy in part to host–microbiome interactions and the challenge of delivering precursors to specific target tissues in adequate concentrations. [^15] This is a critical translational gap that should temper enthusiasm while motivating rigorous trial design.

Second, berberine's clinical evidence base, though derived primarily from relatively small RCTs, is substantially more mature in terms of efficacy outcomes. The mechanistic explanation — AMPK-mediated improvements in insulin sensitivity, lipid metabolism, and adipokine profile — is well-characterized, and the therapeutic effect size in metabolic syndrome is clinically meaningful. [^17] Its oral bioavailability and tissue distribution remain areas of active optimization; dihydroberberine, a reduced derivative with substantially improved intestinal absorption, has demonstrated superior in vivo efficacy in rodent models of insulin resistance.

Third, the NAD⁺/NAMPT/SIRT1 axis intersects with the circadian clock through the CLOCK/BMAL1 transcription factor complex, which directly regulates NAMPT expression in a 24-hour oscillatory pattern. Age-related disruption of circadian rhythms thus feeds into NAD⁺ decline through a pathway independent of oxidative stress or genomic instability. This observation has practical implications: the timing of NAD⁺ precursor administration relative to the circadian phase may influence therapeutic outcomes, a variable rarely controlled in clinical trials.

Fourth, the potential pro-tumorigenic consequences of chronic NAD⁺ supraphysiological elevation — given that tumor cells are highly NAD⁺-dependent — represent a legitimate theoretical concern that has not been dismissed in the literature. The reviewed consensus is that, at the doses studied in clinical trials to date, precursor supplementation raises NAD⁺ within physiological ranges and does not appear to promote tumor growth in the absence of pre-existing malignancy, but longer-duration surveillance data are needed. [^12]

7. CONCLUSION

Targeted mitochondrial medicine, as conceptualized through the lens of the AMPK–NAD⁺–SIRT1 bioenergetic axis, represents one of the most scientifically coherent and therapeutically promising frameworks in contemporary preventive and longevity medicine. The progressive age-related depletion of the intracellular NAD⁺ pool and the parallel attenuation of AMPK responsiveness are not isolated phenomena; they are mechanistically coupled events that collectively erode the mitochondrial competence underlying cardiovascular and metabolic health.

Current evidence supports the clinical use of NAD⁺ precursors (NR and NMN) as safe, bioavailable agents that reliably restore the NAD⁺ pool and show early signals of cardiometabolic benefit. Berberine stands as the best-characterized clinical AMPK activator outside of metformin, with demonstrated efficacy in metabolic syndrome and a well-delineated mechanism of action. PQQ contributes a structurally distinct mitochondriogenic mechanism through the CREB/PGC-1α pathway that is mechanistically synergistic with both pathways. However, formally powered clinical trials combining these agents, with rigorous endpoints including direct measures of mitochondrial function, cardiometabolic biomarkers, and long-term safety, are conspicuously absent and urgently needed.

For the practicing clinician, the principal contribution of this framework is conceptual: that the Krebs cycle and the electron transport chain memorized in the first year of medical school are not historical curiosities but the mechanistic substrate of the most prevalent chronic diseases encountered in daily practice — and that they are amenable, at least in part, to pharmacological and nutraceutical modulation through precisely defined molecular targets. This understanding should be foundational to the modern practice of preventive medicine.

1. Yusri K, Jose S, Vermeulen K, et al. The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. npj Metabolic Health and Disease. 2025. doi:10.1038/s44324-025-00067-0

2. Strømland Ø, Diab J, Ferrario E, et al. The balance between NAD+ biosynthesis and consumption in ageing. Mechanisms of Ageing and Development. 2021;111569. doi:10.1016/j.mad.2021.111569

3. Gomes AP, Price NL, Ling AJY, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. doi:10.1016/j.cell.2013.11.037

4. Burkewitz K, Zhang Y, Mair WB. AMPK at the nexus of energetics and aging. Cell Metabolism. 2014;20(1):10–25. doi:10.1016/j.cmet.2014.03.002

5. Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056–1060. doi:10.1038/nature07813

6. Srivastava S. Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age-related disorders. Clinical and Translational Medicine. 2016;5(1):25. doi:10.1186/s40169-016-0104-7

7. Castro-Portuguez R, Sutphin GL. Kynurenine pathway, NAD+ synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan. Experimental Gerontology. 2020;132:110841. doi:10.1016/j.exger.2020.110841

8. Chini CCS, Tarragó MG, Chini EN. NAD and the aging process: Role in life, death and everything in between. Molecular and Cellular Endocrinology. 2017;455:62–74. doi:10.1016/j.mce.2016.11.003

9. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014;24(8):464–471. doi:10.1016/j.tcb.2014.04.002

10. Fang EF, Lautrup S, Hou Y, et al. NAD+ in aging: Molecular mechanisms and translational implications. Trends in Molecular Medicine. 2017;23(10):899–916. doi:10.1016/j.molmed.2017.08.001

11. Matasic DS, Brenner C, London B. Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease. American Journal of Physiology: Heart and Circulatory Physiology. 2018;314(4):H839–H852. doi:10.1152/ajpheart.00409.2017

12. Abdellatif M, Sedej S, Kroemer G. NAD+ metabolism in cardiac health, aging, and disease. Circulation. 2021;144(22):1795–1817. doi:10.1161/CIRCULATIONAHA.121.056589

13. Burkewitz K, Zhang Y, Mair WB. AMPK at the nexus of energetics and aging. Cell Metabolism. 2014;20:10–25.

14. Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430–441. doi:10.1016/j.cell.2013.06.016

15. Wilson N, Kataura T, Korsgen ME, et al. The autophagy-NAD axis in longevity and disease. Trends in Cell Biology. 2023;33(9):788–802. doi:10.1016/j.tcb.2023.02.004

16. Zhang Y, Ye J. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharmaceutica Sinica B. 2012;2(4):341–349. doi:10.1016/j.apsb.2012.06.010

17. Song Q, Zhou X, Xu K, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Advances in Nutrition. 2023;14(6):1321–1336. doi:10.1016/j.advnut.2023.08.008

18. Reiten OK, Wilvang MA, Mitchell S, et al. Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing. Mechanisms of Ageing and Development. 2021;199:111567. doi:10.1016/j.mad.2021.111567

19. Yaku K, Nakagawa T. NAD+ precursors in human health and disease: current status and future prospects. Antioxidants and Redox Signaling. 2023;39:1133–1149. doi:10.1089/ars.2023.0354

20. Khatri SM, Abdellatif M, Sedej S. Clinical evidence for the use of NAD+ precursors to slow aging. Geromedicine. 2025. doi:10.70401/geromedicine.2025.0008

21. Bhasin S, Seals D, Migaud M, et al. Nicotinamide adenine dinucleotide in aging biology: potential applications and many unknowns. Endocrine Reviews. 2023;44(6):1047–1073. doi:10.1210/endrev/bnad019

22. Helman T, Braidy N. Importance of NAD+ anabolism in metabolic, cardiovascular and neurodegenerative disorders. Drugs & Aging. 2022;39:685–698. doi:10.1007/s40266-022-00989-0

23. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. Diabetes. 2008;57(5):1414–1418. doi:10.2337/db07-1552

24. Lee YS, Kim W, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–2264. doi:10.2337/db06-0006

25. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research. 2006;47(6):1281–1288. doi:10.1194/jlr.M600020-JLR200

26. Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metabolic Syndrome and Related Disorders. 2013;11(5):366–369. doi:10.1089/met.2012.0183

27. Li Y, Wang P, Yuan Z, et al. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. FEBS Letters. 2011;585(13):1989–1994. doi:10.1016/j.febslet.2011.04.051

28. Chowanadisai W, Bauerly KA, Tchaparian E, et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1α expression. Journal of Biological Chemistry. 2009;285(1):142–152. doi:10.1074/jbc.M109.030130

29. Saihara K, Kamikubo R, Ikemoto K, et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1α signaling pathway. Biochemistry. 2017;56(50):6615–6625. doi:10.1021/acs.biochem.7b01185

30. Cheng Q, Chen J, Guo H, et al. Pyrroloquinoline quinone promotes mitochondrial biogenesis in rotenone-induced Parkinson's disease model via AMPK activation. Acta Pharmacologica Sinica. 2020;42:665–678. doi:10.1038/s41401-020-0487-2

31. Sharma P, Meena M, Laskar N. Dual modulation of SIRT1 and AMPK pathways for cardiovascular longevity in the aged. International Journal of Pharmacology and Pharmaceutical Research. 2025;7(2). doi:10.33545/26647184.2025.v7.i2a.56

32. Xiao Y, Xu M, Alimujiang M, et al. Bidirectional regulation of AMP-activated protein kinase activity by berberine and metformin in response to changes in ambient glucose concentration. Journal of Cellular Biochemistry. 2018;120:5656–5665. doi:10.1002/jcb.27312

[^1]: Strømland et al., 2021. The balance between NAD+ biosynthesis and consumption in ageing. Mechanisms of Ageing and Development.

[^2]: Gomes et al., 2013. Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging. Cell.

[^3]: Burkewitz et al., 2014. AMPK at the nexus of energetics and aging. Cell Metabolism.

[^4]: Cantó et al., 2009. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature.

[^5]: Srivastava, 2016. Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age-related disorders. Clinical and Translational Medicine.

[^6]: Castro-Portuguez & Sutphin, 2020. Kynurenine pathway, NAD+ synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan. Experimental Gerontology.

[^7]: Chini et al., 2017. NAD and the aging process: Role in life, death and everything in between. Molecular and Cellular Endocrinology.

[^8]: Imai & Guarente, 2014. NAD+ and sirtuins in aging and disease. Trends in Cell Biology.

[^9]: Abdellatif et al., 2021. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation.

[^10]: Wilson et al., 2023. The autophagy-NAD axis in longevity and disease. Trends in Cell Biology.

[^11]: Zhang & Ye, 2012. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharmaceutica Sinica B.

[^12]: Yaku & Nakagawa, 2023. NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects. Antioxidants and Redox Signaling.

[^13]: Song et al., 2023. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Advances in Nutrition.

[^14]: Bhasin et al., 2023. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocrine reviews.

[^15]: Turner et al., 2008. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I. Diabetes.

[^16]: Brusq et al., 2006. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine Published, JLR Papers in Press, February 28, 2006. Journal of Lipid Research.

[^17]: Li et al., 2011. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3‐L1 adipocytes. FEBS Letters.

[^18]: Chowanadisai et al., 2009. Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry.

[^19]: Saihara et al., 2017. Pyrroloquinoline Quinone, a Redox-Active o-Quinone, Stimulates Mitochondrial Biogenesis by Activating the SIRT1/PGC-1α Signaling Pathway. Biochemistry.

[^20]: Sharma et al., 2025. Dual modulation of SIRT1 and AMPK pathways for cardiovascular longevity in the aged: Rational design and theoretical mechanistic basis of the hybrid compound SIRAMP-21. International journal of pharmacology and pharmaceutical research.

[^21]: Xiao et al., 2018. Bidirectional regulation of adenosine 5′‐monophosphate–activated protein kinase activity by berberine and metformin in response to changes in ambient glucose concentration. Journal of Cellular Biochemistry.